Pharma News
12 Apr 2026 to 18 Apr 2026
Apr 18, 2026
Bayer's Shift in Strategy Relies on Its Pipeline and Intellectual Property - Ad-hoc-news.de
Bayer aims for a 30% pharma margin by 2030, focusing on new drugs Nubeqa and Kerendia, which saw significant revenue growth. However, the company faces challenges from patent expirations of Xarelto and Eylea and ongoing Roundup litigation. Analysts have upgraded Bayer's stock, reflecting improved sentiment amid these transitions.
Apr 18, 2026
This Pharmaceutical Company Has Outperformed the S&P 500 in the Past Ten Years - The Globe and Mail
Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, have seen remarkable sales growth of 99% and 175% in 2025, respectively. However, the company faces increasing competition from Novo Nordisk and Pfizer, and its stock is considered expensive with a P/E ratio of 39x. Analysts caution investors about potential risks as patent protections expire.
Apr 18, 2026
Model Medicines secures US patent for MDL-001 as part of its extensive antiviral intellectual property portfolio.
Model Medicines has received US Patent No. 12,551,475 B2 for its virology program, which includes the broad-spectrum antiviral candidate MDL-001. The patent supports a portfolio of 15 families covering novel antiviral compositions and methods, with protection extending to 2046. MDL-001 has shown efficacy against multiple viral families and is set for an FDA IND application in late 2026.
Apr 17, 2026
Understanding Keytruda: Mechanism of Action and Current Attention in Cancer Treatment | Health News
A global investigation by the International Consortium of Investigative Journalists has scrutinized Merck & Co.'s strategies to extend the exclusivity of its cancer immunotherapy, Keytruda (Pembrolizumab). The findings raise concerns over affordability and access, particularly in India, where treatment costs can reach tens of lakhs. While Keytruda offers targeted cancer treatment, its high price and patient selection criteria complicate access.
Apr 17, 2026
KDDF Aims for FDA Endorsement and a 1 Trillion Won Hit Medication - Seoul Economic Daily
The Korea Drug Development Fund (KDDF), led by Park, aims to enhance drug approvals and commercialization, shifting focus from early-stage research to tangible clinical results. The strategy includes increased support for late-stage trials, AI-based development, and collaboration with global pharmaceutical companies. KDDF seeks to create a sustainable system for producing competitive new drugs, targeting an annual revenue of 1 trillion won.
Apr 17, 2026
Top 11 Pharmaceutical Firms to Watch in 2026 - Money | HowStuffWorks
The pharmaceutical industry, led by major companies, significantly impacts the global economy by developing essential drugs and vaccines. Recent growth has been fueled by rising demand for treatments in cancer, autoimmune, and infectious diseases. However, Big Pharma faces challenges including patent expirations, competition from generics, and scrutiny over pricing.
Apr 17, 2026
US appeals court reinstates Teva's lawsuit against Eli Lilly regarding migraine medication.
A U.S. appeals court has reinstated Teva Pharmaceutical's patent lawsuit against Eli Lilly over their migraine drugs, reversing a previous ruling that invalidated Teva's patents. Lilly's spokesperson stated the company disagrees with the decision but maintains its ability to provide Emgality. The case will return to Massachusetts federal court for further proceedings.
Apr 17, 2026
Saudi Arabia's Generic Pharmaceutical Sector: Affordable Healthcare Solutions, Patent Expirations, and Increasing Demand
Saudi Arabia's generic drug market is projected to grow from USD 4.1 billion in 2025 to USD 8.1 billion by 2034, driven by rising healthcare costs, chronic diseases, and government initiatives. Key developments include Apex Pharma's new facility and Bio-Thera Solutions' partnership with Tabuk Pharmaceutical for BAT2206, a biosimilar to Stelara. The Saudi Food and Drug Authority is streamlining approvals to enhance market access.
Apr 17, 2026
US appellate court reinstates Teva's lawsuit against Eli Lilly regarding migraine medication.
A U.S. appeals court has reinstated Teva Pharmaceutical's lawsuit against Eli Lilly over patent infringement related to their migraine drugs, Ajovy and Emgality. The court reversed a previous ruling that invalidated Teva's patents, which had led to a $176.5 million jury award. The case will return to federal court in Massachusetts for further proceedings.
Apr 17, 2026
Citryll enhances its intellectual property portfolio with the approval of a European patent for CIT-013 aimed at treating ...
Citryll has received a European Patent Office grant for CIT-013, its lead drug candidate targeting extracellular traps in immune-mediated inflammatory diseases. The patent, valid until 2039, strengthens Citryll's portfolio and supports clinical development for conditions like rheumatoid arthritis and hidradenitis suppurativa. CIT-013 is a first-in-class monoclonal antibody with a dual mechanism of action, enhancing trap clearance and inhibiting new formation.
Apr 17, 2026
Affordable drug prices are attainable, but action from Washington is needed urgently.
Amid rising healthcare costs, including a projected 6.5% increase in health benefit costs per employee by 2026, Congress is urged to implement bipartisan reforms to lower drug prices. Proposed legislation like the ETHIC Act and the Biosimilar Red Tape Elimination Act aims to curb patent abuse and promote affordable biosimilars, enhancing competition and accessibility for patients.
Apr 17, 2026
Pharmalittle: Lilly unveils findings on obesity medication, U.K. reduces trial durations - STAT News
Researchers led by Richard DiMarchi and Matthias Tschöp suggest that targeting the GLP-1 hormone may not be necessary for effective weight loss, proposing a new drug that activates GIP and glucagon receptors. Meanwhile, Eli Lilly's weight loss pill Foundayo shows promise in reducing cardiovascular risks in overweight type 2 diabetes patients, easing safety concerns amid competition with Novo Nordisk's Wegovy.
Apr 17, 2026
Dermapharm Holding shares (DE000A2GS5D8): The significance of its emphasis on generics for...
Dermapharm Holding, a German generics manufacturer, is positioned to offer stability amid global pharma supply chain disruptions due to geopolitical tensions and tariffs. With a focus on affordable, high-volume drugs, Dermapharm's stock (ISIN: DE000A2GS5D8) appeals to U.S. investors seeking resilient healthcare exposure. Analysts view the company positively, citing its solid generics pipeline and attractive dividend policy.
Apr 17, 2026
Affordable weight loss medication! Dr. Reddy's receives approval for generic oral semaglutide.
The Indian drug regulator has granted final approval for generic semaglutide tablets, marketed by Torrent Pharma as Sembolic and Semalix, despite ongoing patent infringement claims by Novo Nordisk, which sells Rybelsus. The approval is expected to make semaglutide more affordable, with prices significantly lower than Novo's offerings.
Apr 17, 2026
ANDA Litigation Settlements for Q1 2026 | Robins Kaplan LLP - JDSupra
Numerous pharmaceutical patent cases have concluded with various outcomes. Notably, Bausch & Lomb's Lotemax® and Salix's Xifaxan® saw claims dismissed without prejudice. Boehringer Ingelheim's Jardiance® patents were upheld against USV, while Astellas Pharma's Myrbetriq® and Xtandi® cases resulted in dismissals with prejudice. Harmony Biosciences' Wakix® patents were also affirmed, with multiple parties enjoined from infringement.
Apr 17, 2026
Pfizer Files Lawsuits to Prevent Rivals from Launching Dermatitis Medications - Bloomberg Law News
Pfizer Inc. has filed patent infringement lawsuits against Biocon Ltd., Changzhou Pharmaceutical Factory, and Micro Labs Ltd. over their proposed generics for Cibinqo, a drug used to treat dermatitis. The lawsuits were filed in the US District Court for the District of Delaware after the companies claimed Pfizer's patents were invalid or not infringed by their Abrocitinib products.
Apr 17, 2026
Is the oncology pipeline robust for Bristol-Myers Squibb Company (US0897961004)?
Bristol-Myers Squibb faces patent expirations for key drugs like Eliquis and Opdivo, raising concerns about future revenue. However, the company is investing in next-generation oncology treatments and maintaining a strong pipeline, which could drive growth. Analysts remain cautiously optimistic, emphasizing the importance of successful clinical trials and market execution for sustained investor confidence.
Apr 17, 2026
MSN Labs introduces semaglutide - The Hindu
MSN Laboratories has launched its generic semaglutide, branded as Semabest, in India, priced nearly 50% lower than the original. This pre-filled pen for subcutaneous administration aims to enhance affordability and access for patients, following approval from the Central Drugs Standard Control Organisation (CDSCO).
Apr 17, 2026
AbbVie Stock Falls Below Key 50-Day and 200-Day Moving Averages: Strategies for Investors - The Globe and Mail
AbbVie (ABBV) stock is currently trading below its 50-day and 200-day moving averages, indicating a downtrend. Despite challenges from Humira's patent loss and declining aesthetics sales, AbbVie expects strong growth from its immunology drugs, Skyrizi and Rinvoq, projected to generate over $31 billion in 2026. The company remains well-positioned for long-term growth with a robust pipeline and strategic acquisitions.
Apr 17, 2026
Study reveals that Merck's leading cancer medication exceeded $200,000 annually during Trump's presidency - ICIJ
Merck & Co.'s cancer drug Keytruda has increased in price to $210,000 for a year's treatment, a 6% rise since last year, according to a Senate report. Despite deals with the Trump administration aimed at lowering drug prices, Keytruda remains costly. The report highlights significant price disparities, with the U.S. paying over five times more than Japan for the drug.
Apr 17, 2026
The Latest Weight-Loss Medication Offers Impressive Financial Benefits | Stansberry Research
Eli Lilly's new weight-loss pill, Foundayo, has received FDA approval, positioning it as a game-changer in the weight-loss drug market. Unlike existing injectables like Ozempic and Wegovy, Foundayo is a cost-effective oral medication. The weight-loss drug market is projected to reach $170 billion by 2031, with Eli Lilly also exploring combinations with bimagrumab to enhance muscle retention during weight loss.
Apr 17, 2026
Appeals court alleviates Teva's challenges by overturning decision | Americas
A US district court has permitted significant aspects of a generic drugmaker's lawsuit against a competitor to proceed, while establishing clear boundaries on the scope of the complaint.
Apr 16, 2026
Bayer's Drug Development Progresses as Important Medication Demonstrates Potential - Ad-hoc-news.de
Bayer AG's pharmaceutical division reports strong sales growth for Nubeqa and Kerendia, alongside a successful Phase III trial for the anticoagulant asundexian, which shows promise in reducing ischemic events. The company anticipates post-2026 growth, reaffirming its financial outlook despite potential US import tariffs. Bayer's stock remains robust, reflecting a nearly 96% year-on-year gain.
Apr 16, 2026
Review suggests that Alzheimer medications praised as breakthrough treatments for dementia are ineffective.
A major review by the UK Cochrane policy institute claims that Alzheimer’s drugs, including donanemab and lecanemab, do not significantly improve memory or slow dementia. Critics argue the review is flawed, combining results from failed trials with successful ones. Eli Lilly, the manufacturer of donanemab, defends its efficacy, citing methodological issues in the review.
Apr 16, 2026
[why&next] Keytruda Faces Dual Challenges from U.S. Drug Price Negotiations and Patent Expiration
Merck's Keytruda (pembrolizumab) will face price negotiations under the U.S. Inflation Reduction Act starting in 2029, coinciding with its patent expiry in 2028. This raises concerns for Alteogen, which earns royalties from Keytruda's subcutaneous formulation, as potential price drops could impact its revenue. Experts caution against relying solely on the useful life of intangible assets for revenue forecasts.
Apr 16, 2026
Bayer's Shift in 2026: Balancing Promising Developments with Patent Challenges - Ad-hoc-news.de
Bayer is facing near-term cash flow and patent challenges, particularly from the expiry of Xarelto, while banking on growth from Nubeqa and Kerendia for a post-2026 recovery. Despite a net loss of €3.6 billion in 2025, analysts remain cautiously optimistic, with UBS maintaining a Buy rating. Upcoming events, including the AGM and Q1 report, will be crucial for investor confidence.
Apr 16, 2026
Allahabad High Court Invalidates Uttar Pradesh Government's Extra Experience Requirement for Drug Inspector Positions
The Allahabad High Court has ruled that the Uttar Pradesh government's additional experience requirement for Drug Inspector posts is unconstitutional, emphasizing the primacy of central legislation in pharmaceutical regulation. This decision could impact future recruitment processes in the state.
Apr 16, 2026
Inconsistent insurance coverage for GLP-1 medications deteriorates - InsuranceNewsNet
Obesity medications Wegovy and Zepbound are gaining popularity, but insurance coverage is lagging. Many patients, like Megan Lena, have lost coverage for these drugs, leading to high out-of-pocket costs. Research shows 12 million people lost coverage for each drug. CVS Caremark's formulary changes have exacerbated the issue, leaving patients struggling to afford necessary treatments.
Apr 16, 2026
Is a significant increase in semaglutide usage expected after the price drop? - BusinessToday
The recent expiration of semaglutide patents has led to a surge in generic versions of the obesity drug, significantly reducing prices in India. Companies like Sun Pharma and Dr Reddy’s Laboratories have launched affordable alternatives, with costs dropping to Rs 1,800 monthly. However, challenges remain in ensuring access, physician training, and insurance coverage to effectively address India's obesity and diabetes epidemic.
Apr 16, 2026
The high cost of the cancer medication Keytruda and the true burden of its price - The Week
An investigation by the International Consortium of Investigative Journalists reveals that Merck & Co.'s cancer drug Keytruda, while a breakthrough treatment, is priced prohibitively high, creating global inequities in access. With over 1,200 patents, Merck maintains a monopoly, generating $163 billion in sales since 2014, while many patients resort to crowdfunding or face ethical dilemmas in treatment allocation.
Apr 16, 2026
Navigating the Patent Cliff and Access Costs - The Tufts Daily
The pharmaceutical industry's impending 'patent cliff' poses challenges for patients as blockbuster drugs like Merck's Keytruda face loss of exclusivity, potentially leading to lower costs and better access to medications. However, the effectiveness of this transition depends on how insurers and pharmacy benefit managers implement coverage for biosimilars, which could significantly impact patient affordability and access to essential treatments.
Apr 16, 2026
Major report reveals that dementia medications praised as the 'dawn of a new era' for Alzheimer's are ineffective.
A review by the Cochrane Collaboration has found that Alzheimer's drugs, including donanemab and lecanemab, may offer limited benefits, slowing cognitive decline but not significantly improving patients' daily lives. The analysis, involving over 20,000 patients, highlights risks like brain swelling and high costs, leading the NHS to withhold approval. Experts remain divided on the drugs' effectiveness.
Apr 16, 2026
Model Medicines Receives Initial U.S. Patent for MDL-001 in its Extensive Antiviral Applications...
Model Medicines has received U.S. Patent No. 12,551,475 B2 for its virology program, which includes the broad-spectrum antiviral candidate MDL-001. This patent is part of a comprehensive portfolio that protects novel antiviral compositions and methods through at least 2046. MDL-001 has shown efficacy against multiple viral families, including SARS-CoV-2, and the company plans to file an IND application with the FDA in late 2026.
Apr 16, 2026
Trump's Complete Drug Tariffs: The Overlooked FDA Issue | JD Supra
On April 2, 2026, President Trump announced a 100% tariff on imported branded drugs and key ingredients, posing significant risks for mid-sized pharma and specialty biotech companies. These firms, lacking the leverage of Big Pharma, must navigate complex FDA regulations when shifting manufacturing or suppliers to mitigate tariff impacts. Immediate action is essential to avoid future crises.
Apr 16, 2026
The Dangerous Illusion of Affordable Medications | PYMNTS.com
The U.S. Supreme Court will hear Hikma v. Amarin, addressing whether a generic drug manufacturer can be liable for patent infringement via marketing practices linked to a "skinny label." Jeffrey E. Depp argues that the case highlights misconceptions about drug pricing and competition, emphasizing the need for stable patent laws to encourage innovation rather than solely relying on generics for price reduction.
Apr 16, 2026
Lawsuit filed against cancer drug researcher regarding tools for targeting mutations | Americas
Apr 16, 2026
Chairman Cassidy Speaks at Hearing Focused on Improving Access to Prescription Medications...
U.S. Senator Bill Cassidy, Chairman of the Senate HELP Committee, emphasized the need to lower prescription drug costs during a recent hearing. He advocates for increased competition among generic and biosimilar manufacturers, highlighting the importance of generics in saving families money. Cassidy's agenda includes the Ensuring Timely Access to Generics Act and the Biosimilar Red Tape Elimination Act to enhance affordability.
Apr 16, 2026
KDDF redirects its attention towards early clinical approvals and the integration of AI in its upcoming five-year initiative.
The Korea Drug Development Fund (KDDF) is refocusing its strategy for the 2026-2030 phase to prioritize tangible outcomes, including early clinical approvals and global blockbuster drugs. Achievements from the first phase include 72 investigational new drug approvals and significant technology transfers, such as IM Biologics' IMB-101 and LigaChem's LCB84. KDDF aims to enhance drug development efficiency using AI and support innovative modalities.
Apr 16, 2026
As of the previous year, there were 2,162 new drug candidates in development, serving as the driving force behind the domestic pharmaceutical industry.
The National New Drug Development Project Group (KDDF) announced a significant increase in South Korea's new drug pipelines, reaching 2,162 candidates, driven mainly by bio ventures. The government also launched the National Bioinnovation Committee to enhance the bio industry's competitiveness. The goal is to develop a blockbuster drug by 2030, focusing on antibody-drug conjugates and improving clinical trial processes.
Apr 16, 2026
Inconsistent insurance coverage for GLP-1 medications deteriorates further - capradio.org
Insurance coverage for popular obesity drugs, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, is deteriorating, with millions losing access. CVS Caremark has dropped coverage for both drugs, leading to increased out-of-pocket costs for patients. Experts highlight that restrictive policies and high prices hinder access, forcing many to seek alternative solutions.
Apr 16, 2026
Is a broad acceptance of semaglutide expected after the price drop?
The recent expiration of semaglutide patents has led to a surge in generic versions of the obesity drug, significantly reducing prices in India. Companies like Sun Pharma and Dr Reddy’s Laboratories have launched affordable alternatives, with costs dropping to Rs 1,800 monthly. However, challenges remain in ensuring access, physician training, and insurance coverage to address India's obesity and diabetes epidemic.
Apr 16, 2026
India enforces stricter import regulations on Glufosinate for a period of six months to enhance regulatory control.
India has amended its import policy for Glufosinate and its salts, tightening regulations for six months to enhance oversight. This decision, announced on April 16, 2026, aims to ensure effective regulatory control over the import of this herbicide.
Apr 16, 2026
Canada's Drug Agency advises that public health insurance should include Mounjaro for the treatment of type 2 diabetes.
Canada’s Drug Agency recommends public health plans cover Eli Lilly's Mounjaro for Type 2 diabetes, contingent on a discount from the manufacturer. The report suggests Mounjaro's pricing should align with Ozempic, its competitor. If approved, Mounjaro could cost public plans an estimated $1.97 billion over three years. Eli Lilly plans to engage with the CDA on final recommendations.
Apr 15, 2026
Jiangsu Hengrui Pharmaceuticals (CNE0000014X5): The significance of its emphasis on oncology.
Jiangsu Hengrui Pharmaceuticals is emerging as a leader in oncology drug development, particularly with products like pyrotinib and camrelizumab. The company's focus on innovative therapies positions it well for growth in the global pharma market, offering U.S. investors exposure to China's booming sector without direct risks. Analysts highlight Hengrui's strong pipeline and potential for international expansion.
Apr 15, 2026
Review suggests that Alzheimer medications touted as breakthrough treatments are ineffective.
A major review by the UK Cochrane policy institute claims that Alzheimer’s drugs, including donanemab and lecanemab, do not improve memory or slow dementia, despite their approval in the UK. Critics argue the review is flawed, combining results from ineffective and effective drugs, and emphasize the importance of ongoing research in Alzheimer’s treatment.
Apr 15, 2026
Is Regeneron Pharma's Eylea still competitive despite the presence of biosimilars?
Regeneron Pharmaceuticals faces challenges from biosimilars to its blockbuster drug Eylea, prompting investors to assess its oncology pipeline and new approvals for future growth. Despite competition, Regeneron's strong business model, including partnerships with Sanofi for Dupixent, positions it well. Analysts remain optimistic, but risks from biosimilars and pipeline execution require close monitoring.
Apr 15, 2026
Section 232 Tariffs on Medications: Full Duties Imposed on Patented Pharmaceuticals and Active Pharmaceutical Ingredients Beginning...
Beginning July 31, 2026, a 100% duty will be imposed on certain patented pharmaceuticals and active pharmaceutical ingredients (APIs) under Section 232 national security authority. This includes products listed in the FDA's Orange and Purple Books. Exemptions apply to generic drugs and U.S.-origin products. Companies must assess their exposure and prepare for compliance with these tariffs.
Apr 15, 2026
State committee limited the price of a diabetes medication. Is Ozempic the next target?
A Maryland panel has initiated cost caps for the diabetes drug Jardiance, with plans to address the weight loss drug Ozempic next. The Prescription Drug Affordability Board aims to reduce prescription costs for state and local health plans, potentially saving $16 million for Jardiance and up to $165 million for Ozempic. Lawmakers advocate for broader drug cost controls.
Apr 15, 2026
Inconsistent insurance coverage for GLP-1 medications deteriorates - NPR
Insurance coverage for GLP-1 obesity drugs, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, is deteriorating, with millions losing access. Patients face increased costs and restrictions, such as high BMI requirements for coverage. CVS Caremark has dropped Zepbound, leading to financial strain for many, as they struggle to afford these essential medications.
Apr 15, 2026
Novo Nordisk A/S shares (DK0062498333): How solid is its leading position in the obesity medication market? - Ad-hoc-news.de
Novo Nordisk A/S continues to lead the GLP-1 drug market with its flagship products, Ozempic and Wegovy, driving significant growth in diabetes and obesity treatments. Despite strong demand and a robust pipeline, competition from rivals like Eli Lilly's Zepbound and potential regulatory hurdles pose risks. Investors should monitor supply constraints and ongoing trials as key indicators of future performance.
Apr 15, 2026
Novo Nordisk partners with OpenAI to enhance drug discovery through artificial intelligence | Major Pharmaceutical News
Novo Nordisk faces new challenges following the expiration of its core semaglutide patent in India last week. The company, known for its successful diabetes and weight loss drug, is now strategizing its next steps in the competitive pharmaceutical landscape.
Apr 15, 2026
Market Forces, Rather Than Government Regulations, Will Reduce Medication Costs - National Taxpayers Union
The National Taxpayers Union commended the U.S. Senate Committee on Health for addressing drug affordability through competition. They emphasized the importance of a strong pharmaceutical ecosystem and urged against bureaucratic interventions that could hinder innovation. The NTU supports the Biosimilar Red Tape Elimination Act to enhance market access and cautioned against price controls that could discourage investment in drug development.
Apr 15, 2026
Editorial | The Widespread Use of GLP-1: Science Struggles to Keep Pace - The New York Times
Laurel Schmidt, who suffered from severe postconcussion syndrome for nearly a decade, found relief after using the GLP-1 drug Zepbound, which is also known for weight loss. This class of drugs, including Ozempic and Wegovy, is being explored for various off-label uses, showing promise in treating conditions like long Covid and addiction, despite potential side effects and regulatory challenges.
Apr 15, 2026
The cost of medications such as Keytruda can differ significantly for Americans - USA Today
Merck & Co.'s cancer drug Keytruda starts at $12,000 for a 200 mg dose in the U.S., with total costs potentially exceeding $150,000 depending on various factors such as insurers and providers.
Apr 15, 2026
Bayer AG shares (DE000BAY0017): The significance of its pharmaceutical-focused approach for the U.S. market.
Bayer AG is shifting its focus towards pharmaceuticals, emphasizing high-margin drugs like Xarelto and Kerendia, to stabilize amid challenges in crop science. This strategic pivot, following the Monsanto acquisition, aims to enhance long-term value for investors in the U.S. and English-speaking markets. Analysts view Bayer as a hold, with potential upside linked to litigation progress and pharma growth.
Apr 15, 2026
The cost of medications such as Keytruda can differ significantly for Americans | USA Today Excerpt
On April 15, 2026, USA TODAY's Ken Alltucker discussed the soaring costs of medical treatments in the U.S., highlighting Merck & Co's Keytruda, a cancer drug priced at over $162,000 for a 400 mg dose. The podcast examined the impact of patent protections and the lack of price regulation, contributing to high healthcare expenses for patients and insurers.
Apr 15, 2026
AI Collaborates with Pharmaceutical Industry: Novo Nordisk Partners with OpenAI to Accelerate Drug Development
Novo Nordisk, the Danish pharmaceuticals group known for its anti-obesity drugs Ozempic and Wegovy, has formed a strategic partnership with OpenAI to enhance the development of new medications. This collaboration aims to position Novo Nordisk at the forefront of AI transformation in healthcare, enabling faster delivery of improved treatment options to patients.
Apr 15, 2026
Pune FDA Takes Action: 102 Chemist Licenses Revoked and 286 Suspended for Breaching Drug Regulations
The FDA has cancelled 102 chemist licenses and suspended 286 others in Pune and surrounding districts for serious regulatory violations from April 2025 to March 2026. Eight drug manufacturing units also faced license cancellations. Inspections revealed issues like dispensing without prescriptions and unauthorized sales. Authorities emphasize ongoing enforcement to ensure compliance and public safety in the pharmaceutical sector.
Apr 15, 2026
Amgen Inc. shares (US0311621009): Can its advancements in biotechnology lead to new opportunities?
Amgen Inc. is positioned for growth in the biotech sector, focusing on biologics and targeted therapies. With a strong portfolio including blockbuster drugs like Enbrel and Repatha, Amgen appeals to U.S. and English-speaking investors seeking stability and growth. Analysts highlight its competitive advantages, though risks include patent expirations and regulatory hurdles. Upcoming clinical trials and market dynamics will be crucial for its trajectory.
Apr 15, 2026
Seven Indian companies compete as analysts anticipate a more affordable version of Keytruda within two years.
At least seven Indian manufacturers, including Sun, Hetero, and Intas, are developing generic versions of Merck & Co's cancer drug Keytruda (pembrolizumab), expected to be available by 2028 when the patent expires. Experts highlight the potential for a 70% price drop, improving access amid concerns over counterfeit drugs. The Indian government is also promoting biosimilar development through its Bio Pharma SHAKTI initiative.
Apr 15, 2026
Black Diamond Faces Lawsuit Regarding Patented Methods for Cancer Drug Discovery
HMI Medical Innovations LLC has filed a federal lawsuit against Black Diamond Therapeutics Inc., claiming infringement of six patents related to cancer therapy development. The patents, including US Patent Nos. 8,431,110 and 9,645,137, cover methods for identifying and optimizing compounds targeting drug-resistant cancer proteins. The complaint was filed in the US District Court for the District of Delaware.
Apr 15, 2026
Novartis AG shares (CH0012005267): Can its emphasis on Innovative Medicines drive significant growth?
Novartis AG is positioned for steady growth in immunology, cardiology, and oncology, despite patent cliffs and biosimilar pressures. The company focuses on high-value drugs like Entresto, Cosentyx, and Kisqali, supported by a robust R&D pipeline. With a strong U.S. market presence and a commitment to innovation, Novartis remains a compelling investment for global investors.
Apr 14, 2026
The Supreme Court Battle Regarding Fish Oil May Increase Your Prescription Medication Expenses
The Supreme Court is set to hear the case Hikma v. Amarin, involving generic drugmaker Hikma and Amarin, the maker of Vascepa. The dispute centers on "skinny labeling," which allows generics to enter the market sooner. A ruling favoring Amarin could extend brand monopolies, raising drug prices, while a win for Hikma may preserve access to affordable medications.
Apr 14, 2026
How Merck maintains elevated prices for its leading cancer medication - USA Today
A recent investigation reveals that Merck & Co.'s cancer drug Keytruda can cost patients up to $162,567.74 per treatment in the U.S., despite a list price of $24,000. Merck employs tactics like extensive patenting to maintain high prices, while blaming middlemen for inflated costs. The drug's pricing practices raise concerns about affordability and access for cancer patients.
Apr 14, 2026
Chhattisgarh FDA Takes Action Against Counterfeit Antibiotics Operation: Three Suspects Arrested, Including a Major Player...
The Chhattisgarh FDA has arrested three individuals, including a key supplier, in a crackdown on a counterfeit antibiotics racket following a four-month investigation. This operation highlights the government's commitment to combating the illegal drug trade and ensuring public health safety.
Apr 14, 2026
Bombay High Court Overturns NPPA Requests: Price Limits of DPCO 2013 Are Applicable Solely to ...
The Bombay High Court has ruled that the price ceilings under the Drugs (Prices Control) Order, 2013 (DPCO 2013) apply solely to formulations listed in the First Schedule, providing significant relief to pharmaceutical manufacturers. This decision quashes demands from the National Pharmaceutical Pricing Authority (NPPA).
Apr 14, 2026
Pharmaceutical considerations in the development of Clivas tablets: assessing quality, stability, and safety.
A study focused on the pharmaceutical development of rosuvastatin calcium (Clivas) in 10 mg and 20 mg film-coated tablets. The research aimed to optimize the drug's composition using amorphous forms and specific excipients to enhance solubility and stability. Comparisons were made with the reference drug Crestor® and generics, highlighting the benefits of mannitol and direct compression technology for improved stability.
Apr 14, 2026
The emerging competition in space: drug development in zero gravity - Healthcare Investors
The UK is advancing in-space pharmaceutical manufacturing, highlighted by the Artemis II mission. The UK Space Agency, alongside the MHRA, is fostering technologies for drug development in microgravity. Notable examples include Merck's Keytruda, which has seen formulation advancements through space research. Companies like BioOrbit and Varda Space Industries are emerging as key players in this evolving sector.
Apr 14, 2026
Government to Restructure CDSCO and Recruit Over 1,500 Subject Matter Experts - Medical Dialogues
Union Minister J P Nadda emphasized India's potential to lead in the evolving global pharmaceutical landscape, focusing on biologics, biosimilars, and specialty medicine. He highlighted the government's commitment to innovation and R&D, including the Biopharma SHAKTI initiative with a Rs 10,000 crore investment. Minister Anupriya Patel announced plans to restructure the CDSCO and enhance drug discovery through AI and clinical trial networks.
Apr 14, 2026
GSK's Mo-rez Demonstrates Significant Tumor Shrinkage Results, Forecasted as a Promising Cancer Treatment.
GSK's experimental cancer drug Mo-rez shows promising results, shrinking tumors in 62% of platinum-resistant ovarian cancer patients and 67% in endometrial cancer cases. GSK's oncology head, Hesham Abdullah, believes it has blockbuster potential. The drug, an antibody-drug conjugate targeting the B7H4 protein, was licensed from Hansoh Pharma and is undergoing late-stage trials.
Apr 14, 2026
PannTheraPi Reveals Major Advances in Clinical Development and Strategic Achievements
PannTheraPi has filed a regulatory submission to initiate a Phase 2a trial for its drug candidate PTI5803, targeting focal cortical dysplasia (FCD), a severe epilepsy form. The company also secured a European patent for PTI5803's use in epilepsy and appointed Sophie Binay as General Manager and Chief Scientific Officer to enhance its clinical strategy.
Apr 14, 2026
Forecast for the Generic Oncology Drug Market by 2031: Trends and Growth Insights - openPR.com
The global Generic Oncology Drugs Market is projected to grow from $24.78 billion in 2022 to $42.43 billion by 2031, at a CAGR of 6.3%. This growth is driven by rising cancer prevalence, cost-effectiveness of generics, patent expirations, and government support. Key players include Teva Pharmaceutical, Sandoz, and Sun Pharmaceutical.
Apr 14, 2026
Amgen Inc. shares (US0311621009): Can the momentum from its obesity medication lead to further gains?
Amgen Inc. is positioned for growth with its focus on innovative therapies for rare diseases and obesity treatments, including the promising MariTide. The company maintains a strong revenue base from established drugs like Enbrel and Prolia, while its diversified portfolio and robust pipeline support investor confidence. Analysts suggest a positive outlook, with potential for significant upside amid competitive pressures.
Apr 14, 2026
Hikma Claims Cox Decision Strengthens 'Skinny Label' Argument - Law360 Healthcare Authority
Hikma Pharmaceuticals USA Inc. has informed the U.S. Supreme Court that a recent ruling favoring an internet company in a copyright case strengthens its challenge against a patent, supporting its 'skinny label' strategy.
Apr 14, 2026
Projection for the Generic Oncology Medications Market by 2031 - Developments and Trends
The global Generic Oncology Drugs Market is projected to grow from $24.78 billion in 2022 to $42.43 billion by 2031, at a CAGR of 6.3%. This growth is driven by rising cancer prevalence, cost-effectiveness of generics, patent expirations, and government support. Key players include Teva Pharmaceutical Industries, Sandoz, and Sun Pharmaceutical Industries.
Apr 14, 2026
Clearmind (Nasdaq: CMND) CMND-100 achieves important safety milestone in AUD study - Stock Titan
Clearmind Medicine Inc. announced that its drug candidate CMND-100 has met the primary endpoint in an FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. The trial demonstrated a high safety profile and good tolerability, supporting CMND-100 as a potential non-hallucinogenic treatment option. Clearmind is focused on developing neuroplastogen-derived therapeutics.
Apr 14, 2026
Novartis AG shares (CH0012005267): Does its pipeline of innovative medications have the potential to drive new growth?
Novartis AG is enhancing its portfolio with innovative therapies in cardiology, oncology, and immunology, positioning itself as a stable investment amid market volatility. Key products like Entresto and Cosentyx drive revenue growth, while the company’s focus on R&D and generics through Sandoz strengthens its competitive edge. Analysts view Novartis positively, highlighting its resilience and potential for long-term growth.
Apr 14, 2026
AstraZeneca plc shares (GB0009895292): Can their leadership in oncology lead to new opportunities?
AstraZeneca plc is poised for sustained growth through its focus on oncology, rare diseases, and bioPharmaceuticals, despite impending patent expirations on drugs like Nexium and Symbicort. With strong U.S. revenue and a robust pipeline, including products like Enhertu and Imfinzi, the company remains a key player for investors in English-speaking markets. Analysts maintain positive outlooks, emphasizing its competitive edge in precision oncology.
Apr 14, 2026
Two Novel Medications Provide Promise for Pancreatic Cancer Treatment - AOL.com
Revolution Medicines' daraxonrasib and Actuate Therapeutics' elraglusib show promise in improving pancreatic cancer survival rates. Daraxonrasib, targeting KRAS mutations, increased survival to 13.2 months, while elraglusib, administered via IV, doubled one-year survival. Both drugs represent significant advancements in treatment options for a disease with historically low survival rates, offering hope for future therapies.
Apr 14, 2026
J&J's Q1 earnings surpass expectations despite underwhelming Stelara sales - WTAQ
Johnson & Johnson reported a strong first quarter, exceeding earnings expectations with $24.1 billion in revenue, driven by robust sales of cancer drug Darzalex and psoriasis treatment Tremfya. The company also launched the oral psoriasis treatment Icotyde, which has seen rapid adoption. Despite a decline in Stelara sales due to biosimilar competition, J&J raised its full-year revenue forecast to approximately $100.8 billion.
Apr 14, 2026
The significance of Bristol-Myers Squibb Company's (US0897961004) leadership in oncology.
Bristol-Myers Squibb is focusing on its oncology portfolio, particularly drugs like Opdivo and Eliquis, to drive revenue amid patent expirations. The company’s strategy emphasizes depth in oncology, positioning it favorably for U.S. and English-speaking investors. Analysts view the stock positively, despite potential risks from patent cliffs and competition in immuno-oncology.
Apr 14, 2026
Amgen Inc. shares (US0311621009): Can the momentum of its obesity medication maintain long-term growth?
Amgen Inc. is expanding into obesity treatments with its new drug MariTide, aiming to reshape its growth amid increasing biotech competition. The company, known for established products like Enbrel and Repatha, is focusing on diversifying its portfolio while navigating challenges from rivals like Eli Lilly and Novo Nordisk. Analysts remain cautiously optimistic about Amgen's long-term growth potential.
Apr 14, 2026
ETHIC Act Aims to Tackle Patent Clusters and Reduce Prescription Drug Costs - Public Citizen
The ETHIC Act aims to combat monopoly abuse in the pharmaceutical industry by allowing branded drug companies to assert only one patent per family in litigation. Experts, led by Public Citizen, argue this legislation would reduce patent thickets, lower drug prices, and increase access to affordable generic and biosimilar options for patients.
Apr 13, 2026
How Merck transformed its groundbreaking medication into a commercial success while making it unaffordable for cancer patients globally.
Merck & Co. CEO Robert M. Davis announced plans to reduce prices on some drugs, but not on Keytruda (pembrolizumab), which generated $31.7 billion in 2025. An investigation reveals Merck's tactics to maintain high prices and delay generics, exacerbating global inequities in cancer treatment access. Keytruda's costs remain unaffordable for many, with prices ranging from $65,000 to $208,000 annually.
Apr 13, 2026
SEE: The strategies Merck employs to maintain high prices for Keytruda - ICIJ
Cancer Calculus highlights the challenges families face in accessing Merck’s innovative cancer treatment due to its high cost, revealing the strain on healthcare systems worldwide.
Apr 13, 2026
Fraudsters profit from the top-selling cancer medication - ICIJ
A recent investigation revealed that counterfeit versions of Keytruda, an immunotherapy drug produced by Merck & Co., have infiltrated global markets, endangering cancer patients. The report highlighted cases in Nepal and Mexico, where patients unknowingly received fake medications, leading to severe health consequences. Merck faces scrutiny over high drug prices, which contribute to the demand for counterfeit alternatives.
Apr 13, 2026
Merck's Keytruda: A life-saving medication highlighting global disparities - DW.com
A cross-border investigation by DW and ICIJ reveals how Merck's cancer drug Keytruda (pembrolizumab) has become a best-seller while many patients struggle to access it due to high costs and patent protections. The investigation highlights disparities in treatment access globally, with prices ranging from $850 to over $6,000 per vial, exacerbating inequalities in healthcare.
Apr 13, 2026
Merck's Keytruda: A life-saving medication highlighting global disparities - Yahoo News UK
An international investigation by the ICIJ reveals how Merck's cancer drug Keytruda (pembrolizumab) symbolizes unequal access to life-saving treatments. Despite generating $31.7 billion in sales in 2025, high costs and patent protections limit availability, forcing patients to seek legal recourse or crowdfunding. The findings highlight systemic issues in global healthcare, emphasizing disparities based on geography and income.
Apr 13, 2026
Chinese Herbal Remedies for Cervical Spondylosis | IJGM - Dove Medical Press
A recent study systematically analyzed 31 Chinese patent medicines (CPM) for cervical spondylosis, highlighting their therapeutic effects, safety, and clinical research status. Key findings include significant price variations, predominance of oral formulations, and methodological flaws in existing studies. The research emphasizes the need for standardized outcome measures, improved safety information, and multicenter trials to enhance the efficacy and safety of CPM treatments.
Apr 13, 2026
Are fake cancer medications arriving in India prior to patent expiration? Keytruda sparks safety issues.
Counterfeit versions of Keytruda, a leading cancer immunotherapy developed by Merck & Co., have been found in various markets, including India, raising concerns about patient safety and distribution gaps. As patents expire between 2028 and 2030, Indian companies like Biocon and Dr. Reddy’s Laboratories are preparing for a biosimilar market, while counterfeit drugs pose significant health risks.
Apr 13, 2026
Surge in Diversions of Codeine Syrup and Narcotic Pills Across the Country; Law Enforcement Faces Challenges as DCC...
Codeine-based cough syrups and narcotic pills like Tramadol, Nitrazepam, and Tapentadol are experiencing a surge in diversion across the U.S., posing significant challenges for law enforcement. The proposed DCC portal aimed at addressing this issue is facing delays, exacerbating the problem.
Apr 13, 2026
Keytruda: What is the actual price of the top-selling cancer medication globally? - TBIJ
Keytruda, the bestselling cancer drug from MSD, generates approximately $30 billion annually but remains unaffordable for many patients. In the UK, the NHS reportedly pays up to five times the fair price for the drug, with one patient's treatment costing over £180,000. This financial strain comes amid a healthcare crisis, with nearly 20,000 patients dying while awaiting treatment.
Apr 13, 2026
The top revenue-generating medication from major pharmaceutical companies: exploring the financial success of a single drug - TBIJ
MSD's Keytruda, a leading cancer treatment, is under scrutiny for exploiting the patent system with over 1,200 patents globally, potentially stifling competition until 2042. Critics claim the company promotes unnecessary higher dosages, leading to exorbitant costs for patients. Reports highlight inequities in access, with many unable to afford the drug in countries like Brazil, India, and South Africa.
Apr 13, 2026
Affordable Ozempic is on the way, presenting both advantages and challenges for Australians - SMH
In Australia, the cost of Ozempic, a popular weight loss drug by Novo Nordisk, is set to plummet after patent expirations in 2029 and 2031, allowing generics to enter the market. This shift could make the drug accessible for long-term use, impacting global markets and potentially leading to social changes, including increased divorce rates linked to rapid weight loss.
Apr 13, 2026
Affordable Ozempic is on the way, presenting both advantages and challenges for Australians - The Age
In Australia, the cost of Ozempic, a popular weight loss drug by Novo Nordisk, is set to plummet after patent expirations in 2029 and 2031, allowing generics to enter the market. This shift could make the drug accessible for long-term use, impacting global markets and potentially leading to social changes, including increased divorce rates linked to rapid weight loss.
Apr 13, 2026
Astellas Pharma Inc. versus Ascent Pharmaceuticals, Inc. | Robins Kaplan LLP - JDSupra
Astellas Pharma Inc. successfully defended its patents for Myrbetriq® (mirabegron extended-release tablets) against Ascent Pharms., Inc. in a recent court ruling. The court found that Ascent's ANDA product infringed on Astellas' patents, rejecting claims of invalidity based on unpatentable subject matter, anticipation, and obviousness. The ruling reinforces Astellas' patent protections for treating overactive bladder.
Apr 13, 2026
Roche Holding AG shares (CH0012032048): Can their leadership in oncology lead to new opportunities?
Roche Holding AG continues to lead in cancer treatments, with a strong portfolio including Avastin and Herceptin, driving steady growth amid a competitive biotech landscape. The company’s focus on oncology and diagnostics positions it well for future demand, despite pipeline risks and pricing pressures. Analysts maintain positive ratings, highlighting Roche's resilience and dividend appeal for U.S. investors.
Apr 13, 2026
How Merck leverages patents to sustain the high cost of Keytruda - ICIJ
The ICIJ's investigation into Merck & Co.'s Keytruda reveals a complex network of patents designed to maintain market exclusivity. While Keytruda's original patents expire in 2028, Merck's strategy of "evergreening" has resulted in 50 active U.S. patents that could extend its dominance until 2042, potentially delaying the entry of affordable biosimilars.
Apr 13, 2026
Merck & Co., Inc. stock (US58933Y1055): Is the true challenge now the supremacy of Keytruda?
Merck & Co., Inc. faces scrutiny as it navigates patent cliffs and oncology leadership, with its blockbuster drug Keytruda driving significant revenue. While the company’s diversified portfolio, including vaccines like Gardasil, offers stability, concerns about pipeline diversification and patent expirations persist. Analysts maintain a positive outlook, emphasizing Merck's potential for mid-single-digit revenue growth amid healthcare volatility.
Apr 13, 2026
Regeneron enters the radiopharmaceutical sector with a $2.1 billion deal with Telix - Fierce Biotech
Regeneron has partnered with Telix Pharmaceuticals, investing $40 million to develop four solid tumor programs using Telix's radiopharmaceutical platform. The collaboration may expand to four additional programs, with potential earnings for Telix reaching $2.1 billion. Regeneron aims to combine these radiopharmaceuticals with its Libtayo drug to enhance treatment options for cancers like lung cancer.
Apr 13, 2026
Keytruda treats 22 types of cancer, yet remains inaccessible for the majority of patients in India - India Today
Pembrolizumab, marketed as Keytruda, remains largely inaccessible to cancer patients in India despite its recent FDA approval for ovarian cancer. High costs, driven by patent protections held by Merck & Co until June 2028, limit access to this life-extending therapy. Currently, less than 3% of Indian cancer patients can afford such treatments, highlighting a significant healthcare disparity.
Apr 13, 2026
Pharmalittle: Promising pancreatic cancer findings, Replimune medication not approved - STAT News
Revolution Medicines' targeted pill, daraxonrasib, has shown promising results for metastatic pancreatic cancer, with patients living a median of 13.2 months compared to 6.7 months for chemotherapy. The company plans to seek FDA approval using a National Priority Review Voucher. Meanwhile, Replimune's experimental treatment for advanced skin cancer faces scrutiny from the FDA amid concerns over its efficacy when combined with Bristol Myers Squibb's Opdivo.
Apr 13, 2026
FDA Greenlights Foundayo, a New Oral Weight-Loss Medication Similar to Ozempic - ColombiaOne.com
The FDA has approved Eli Lilly's weight-loss pill, Foundayo (orforglipron), marking its entry into the obesity treatment market. Foundayo competes with Novo Nordisk’s Wegovy and offers flexible dosing. Patients may lose an average of 12% body weight over 72 weeks. Prices range from $149 to $349 monthly, with potential Medicare access at $50.
Apr 13, 2026
Roche Holding AG shares (CH0012032048): Can its diagnostic capabilities compensate for ...
Roche Holding AG's integrated pharma-diagnostics model offers stability for investors, with significant U.S. revenue reliance. The company’s portfolio includes blockbuster drugs like Ocrevus and Hemlibra, alongside a strong diagnostics division. Analysts view Roche favorably for its defensive qualities and pipeline depth, though risks include pipeline failures and biosimilar erosion. Roche's stock (CH0012032048) remains a solid choice amid market volatility.
Apr 13, 2026
Novo Nordisk A/S shares (DK0062498333): Can the leading position in obesity medications lead to significant growth?
Novo Nordisk A/S continues to dominate the diabetes and obesity treatment market with its blockbuster drugs Ozempic and Wegovy, despite rising competition from Eli Lilly. The company’s focus on GLP-1 agonists and significant R&D investment positions it well for long-term growth. However, supply constraints and patent challenges pose risks for investors in the U.S. and English-speaking markets.
Apr 13, 2026
AstraZeneca PLC shares (US6549022043): Can their leadership in oncology lead to new opportunities?
AstraZeneca PLC is leveraging its strong oncology portfolio, including drugs like Enhertu, Imfinzi, and Tagrisso, to drive growth amid patent expirations. The company focuses on high-margin therapeutics and precision medicine, appealing to U.S. investors seeking stability. Analysts view AstraZeneca favorably, though risks from patent cliffs and regulatory hurdles remain. Upcoming catalysts include Phase III data for datopotamab deruxtecan.
Apr 12, 2026
Apotex receives preliminary FDA approval for its generic version of Ozempic, while pharmaceutical companies anticipate a decision from Health Canada.
Apotex Inc. has received tentative FDA approval for a generic version of Ozempic, containing semaglutide, six years before the patent expires. Developed with Orbicular Pharmaceutical Technologies, this approval grants Apotex a potential 180-day market exclusivity. Meanwhile, Canada has seen no generic approvals since legalizing them in January, with nine applications pending, including three from Apotex.
Apr 12, 2026
GSK identifies significant potential in targeted cancer treatment following encouraging initial results.
GSK's experimental cancer drug Mo-rez shows promising results, shrinking tumors in 62% of platinum-resistant ovarian cancer patients and 67% in endometrial cancer cases. GSK's oncology head, Hesham Abdullah, believes it has blockbuster potential. The drug, licensed from Hansoh Pharma, targets the B7H4 protein and is part of GSK's expanding oncology portfolio, with further trials planned.
Apr 12, 2026
GSK announces encouraging initial findings from its drug trial for ovarian and uterine cancer.
GSK announced promising results for its cancer treatment Mocertatug Rezetecan (Mo-Rez), which shrank or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients in early trials. The company plans to advance to late-stage trials, aiming for peak sales over £2bn. GSK's CEO Luke Miels emphasizes accelerated drug development in oncology.
Apr 12, 2026
Eli Lilly's Two-Faceted Approach: Introducing a New Medication and Investing $6.3 Billion
Eli Lilly has launched its oral weight-loss drug Foundayo (orforglipron) in the U.S., demonstrating a 12.4% average weight reduction in trials. The company also announced a $6.3 billion acquisition of Centessa Pharmaceuticals, targeting sleep disorder treatments. With Q1 earnings due April 30, analysts expect significant revenue growth, despite potential pricing pressures and competition from Novo Nordisk's Wegovy.
Apr 12, 2026
Biogen Inc. (US09062X1037): Can its neurology pipeline lead to a resurgence?
Biogen Inc. is focusing on Alzheimer's and multiple sclerosis (MS) treatments to navigate potential patent cliffs and drive growth. With a strong U.S. revenue base, the company aims to leverage its innovative therapies and strategic partnerships, particularly in neurology. Analysts maintain a positive outlook, despite risks from patent expirations and competition. Biogen's stock (US09062X1037) remains a key player for U.S. biotech investors.
Apr 12, 2026
GSK accelerates development of cancer medication that could generate billions in yearly revenue - The Times
GSK has announced promising early trial results for its new gynaecological cancer drug, Mo-Rez, which showed tumor reduction in 62% of ovarian and 67% of endometrial cancer patients. The company plans to initiate five large-scale global trials, aiming for blockbuster status with potential annual sales exceeding £2 billion. GSK licensed Mo-Rez from China's Hansoh and is manufacturing it outside China.
Apr 12, 2026
India Pharma 2026 scheduled for April 13-14 in New Delhi - Drug Regulation Authority
The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, will host the 9th edition of India Pharma 2026 on April 13-14 in New Delhi, in collaboration with the Federation of Indian Chambers of Commerce and Industry.
Apr 12, 2026
This Major Medication Has Improved - AOL - Yahoo
A new test has positively impacted the outlook for Tysabri, a leading multiple sclerosis drug, benefiting both investors and patients. Analysts David Williamson and Austin Smith discuss this development, highlighting the drug's makers, including Teva Pharmaceutical Industries and Pfizer, in their analysis. The Motley Fool continues to recommend various health-care stocks, including Quest Diagnostics and Elan.
Apr 12, 2026
Aurobindo Pharma Ltd's stock (INE406A01037): Can its expansion in the U.S. generics market effectively drive growth?
Aurobindo Pharma, a key player in the U.S. generics market, generates over half its revenue from affordable medications supplied to major chains like Walmart and CVS. The company is focusing on complex generics and injectables to enhance profitability amid ongoing drug shortages. Analysts maintain a cautiously optimistic outlook, highlighting Aurobindo's potential for growth despite execution risks and regulatory challenges.
Apr 12, 2026
NFI 2026 Draft Urges Care Regarding Children's Cough Syrups, Reports DrugsControl Media Services
The draft National Formulary of India (NFI) 2026 advises against prescribing cough and cold medications to children under 2 years, emphasizing caution in the use of paediatric cough syrups. This recommendation follows media reports highlighting safety concerns regarding these medications for young children.
